ERBB2 and breast cancer: Consequently, trastuzumab + pertuzumab and a taxane is recommended as the first-line treatment of metastatic or unresectable HER2+ BC by the National Comprehensive Cancer Network [13] (NCCN) and the European Society for Medical Oncology [14] (ESMO) guidelines.